Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 2
2004 2
2005 1
2006 2
2007 5
2008 1
2009 1
2011 8
2012 4
2013 6
2014 8
2015 6
2016 10
2017 8
2018 9
2019 7
2020 7
2021 8
2022 9
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dunleavy K, et al. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. Lancet Haematol. 2018. PMID: 30501868 Free PMC article. Clinical Trial.
BACKGROUND: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. ...INTERPRETATION: In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B …
BACKGROUND: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 g …
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality.
Jenkins DJA, Dehghan M, Mente A, Bangdiwala SI, Rangarajan S, Srichaikul K, Mohan V, Avezum A, Díaz R, Rosengren A, Lanas F, Lopez-Jaramillo P, Li W, Oguz A, Khatib R, Poirier P, Mohammadifard N, Pepe A, Alhabib KF, Chifamba J, Yusufali AH, Iqbal R, Yeates K, Yusoff K, Ismail N, Teo K, Swaminathan S, Liu X, Zatońska K, Yusuf R, Yusuf S; PURE Study Investigators. Jenkins DJA, et al. N Engl J Med. 2021 Apr 8;384(14):1312-1322. doi: 10.1056/NEJMoa2007123. Epub 2021 Feb 24. N Engl J Med. 2021. PMID: 33626252
Tobacco Use Disorders.
Camenga DR, Klein JD. Camenga DR, et al. Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):445-60. doi: 10.1016/j.chc.2016.02.003. Epub 2016 Apr 8. Child Adolesc Psychiatr Clin N Am. 2016. PMID: 27338966 Free PMC article. Review.
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, Zhu M, Whitlock JA, Gore L. von Stackelberg A, et al. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27998223 Clinical Trial.
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precur …
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety …
Apolipoproteins B and A1 in Ischemic Stroke Subtypes.
Kalani R, Krishnamoorthy S, Deepa D, Gopala S, Prabhakaran D, Tirschwell D, Sylaja PN. Kalani R, et al. J Stroke Cerebrovasc Dis. 2020 Apr;29(4):104670. doi: 10.1016/j.jstrokecerebrovasdis.2020.104670. Epub 2020 Feb 10. J Stroke Cerebrovasc Dis. 2020. PMID: 32057650 Free PMC article.
INTRODUCTION: Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and intracranial atherosclerotic disease. We sought to assess the relationship between serum levels of apolipoprotein B, apolipoprotein A …
INTRODUCTION: Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and …
Synthesis, optimization and applications of ZnO/polymer nanocomposites.
Ponnamma D, Cabibihan JJ, Rajan M, Pethaiah SS, Deshmukh K, Gogoi JP, Pasha SKK, Ahamed MB, Krishnegowda J, Chandrashekar BN, Polu AR, Cheng C. Ponnamma D, et al. Mater Sci Eng C Mater Biol Appl. 2019 May;98:1210-1240. doi: 10.1016/j.msec.2019.01.081. Epub 2019 Jan 21. Mater Sci Eng C Mater Biol Appl. 2019. PMID: 30813004 Review.
Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma.
Swetha M, Keerthana CK, Rayginia TP, Nath LR, Haritha NH, Shabna A, Kalimuthu K, Thangarasu AK, Aiswarya SU, Jannet S, Pillai S, Harikumar KB, Sundaram S, Anto NP, Wu DH, Lankalapalli RS, Towner R, Isakov N, Deepa SS, Anto RJ. Swetha M, et al. Pharmaceuticals (Basel). 2022 May 22;15(5):636. doi: 10.3390/ph15050636. Pharmaceuticals (Basel). 2022. PMID: 35631464 Free PMC article.
We previously reported the remarkable potency of uttroside B (Utt-B), saponin-isolated and characterized in our lab from Solanum nigrum Linn, against HCC. ...Our data indicate that Utt-B holds an augmented anti-HCC efficacy over sorafenib. Our previous report …
We previously reported the remarkable potency of uttroside B (Utt-B), saponin-isolated and characterized in our lab from Solan …
The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs.
Maestre G, Carrillo M, Kalaria R, Acosta D, Adams L, Adoukonou T, Akinwande K, Akinyemi J, Akinyemi R, Akpa O, Alladi S, Allegri R, Arizaga R, Arshad F, Arulogun O, Babalola D, Baiyewu O, Bak T, Bellaj T, Boshe J, Brayne C, Brodie-Mends D, Brown R, Cahn J, Cyrille N, Damasceno A, de Silva R, de Silva R, Djibuti M, Dreyer AJ, Ellajosyula R, Farombi T, Fongang B, Forner S, Friedland R, Garza N, Gbessemehlan A, Georgiou EE, Gouider R, Govia I, Grinberg L, Guerchet M, Gugssa S, Gumikiriza-Onoria JL, Gustafson D, Hogervorst E, Hornberger M, Ibanez A, Ihara M, Ismail O, Issac T, Jönsson L, Kaputu C, Karanja W, Karungi J, Tshala-Katumbay D, Kunkle B, Lee JH, Leroi I, Lewis R, Livingston G, Lopera F, Lwere K, Manes F, Mbakile-Mahlanza L, Mena P, Miller B, Millogo A, Mohamed A, Musyimi C, Mutiso V, Nakasujja N, Ndetei D, Nightingale S, Njamnshi AK, Novotni G, Nyamayaro P, Nyame S, Ogeng'o J, Ogunniyi A, Okada De Oliveira M, Okubadejo N, Orrell M, Orunmuyi A, Owolabi M, Paddick S, A Pericak-Vance M, Pirtosek Z, Potocnik F, Preston B, Raman R, Ranchod K, Rizig M, Rosselli M, Deepa R, Roy U, Salokhiddinov M, Sano M, Sarfo F, Satizabal CL, Sepulveda-Falla D, Seshadri S, Sexton C, Skoog I, St G… See abstract for full author list ➔ Maestre G, et al. Alzheimers Dement. 2023 Mar 11. doi: 10.1002/alz.13025. Online ahead of print. Alzheimers Dement. 2023. PMID: 36905253 No abstract available.
Prevalence of vitamin B(12) deficiency in South Indians with different grades of glucose tolerance.
Jayashri R, Venkatesan U, Rohan M, Gokulakrishnan K, Shanthi Rani CS, Deepa M, Anjana RM, Mohan V, Pradeepa R. Jayashri R, et al. Acta Diabetol. 2018 Dec;55(12):1283-1293. doi: 10.1007/s00592-018-1240-x. Epub 2018 Oct 13. Acta Diabetol. 2018. PMID: 30317438
Vitamin B(12) 191 pg/ml was defined as absolute vitamin B(12) deficiency and vitamin B(12) > 191 pg/ml and 350 pg/ml as borderline deficiency. ...Among individuals with NGT, prediabetes and T2DM, vitamin B(12) negatively correlated with homocysteine …
Vitamin B(12) 191 pg/ml was defined as absolute vitamin B(12) deficiency and vitamin B(12) > 191 pg/ml and 350 pg/ml …
108 results